As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

Stock buy­backs are not to be per­mit­ted for com­pa­nies that will be bailed out in the coro­n­avirus stim­u­lus pack­age, Con­gres­sion­al lead­ers have sig­naled. To what …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER